Jaspreet Jaggi

Jaspreet Jaggi, M.D., Ph.D.,joined BeiGene in October 2020 as Senior Vice President and Head, Clinical Portfolio Strategy. In this role, Dr. Jaggi is responsible for scientific and strategic evaluation, and clinical development strategy for external innovation and investments, and to help guide BeiGene’s growth strategies for internal portfolio compounds. Prior to joining BeiGene, Dr. Jaggi served in various clinical evaluation and clinical development leadership roles at Novartis for approximately 10 years. Most recently, as Vice President and Global Head of Oncology Clinical Evaluation, he led the scientific and strategic evaluation for both the internal oncology pipeline as well as external innovation. At Novartis, he spearheaded the scientific and clinical evaluation of the company’s multiple partnerships including the notable acquisitions of GSK Oncology, AAA, Endocyte, CoStim, and Admune, as well as strategic investments in CAR-T therapy and multiple in-licensing agreements. Dr. Jaggi also served as the Global Clinical Program Head for Oncology Biosimilars, overseeing an integrated clinical development team across Sandoz and Novartis. Before Novartis, he worked in various clinical development roles at Bristol Myers Squib and Pfizer. Dr. Jaggi received his medical degree from Grant Medical College in Mumbai, and a Ph.D. in Pharmacology from Weill Cornell Medical College and Memorial Sloan Kettering’s joint program. He was a Ludwig Center for Cancer Immunotherapy fellow at Memorial Sloan Kettering Cancer Center.